Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. All News
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
Delayed Nasdaq  -  04:00 2022-09-29 pm EDT
136.28 USD   -4.32%
09/27Asian ADRs Move Higher in Tuesday Trading
MT
09/27BeiGene Posts $1.0 Billion in Net Losses For H1
MT
09/22Beigene, Ltd. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
All news about BEIGENE, LTD.
09/27Asian ADRs Move Higher in Tuesday Trading
MT
09/27BeiGene Posts $1.0 Billion in Net Losses For H1
MT
09/22Beigene, Ltd. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/20NICE Recommends BeiGene's BRUKINSA for Patients with Waldenstrom's Macroglobulinemia wh..
AQ
09/20BeiGene Receives Positive CHMP Opinion for BRUKINSA for the Treatment of Adults with Ma..
AQ
09/20BeiGene Says UK's National Institute for Health and Care Excellence Backs Approval of L..
MT
09/20England Approves BeiGene's Lymphoma Medication
MT
09/20U.K. National Institute for Health and Care Excellence Approves BeiGene's BRUKINSA As R..
MT
09/19Chinese Biotech BeiGene's Blood Cancer Therapy Wins Recommendations in EU, UK
MT
09/19NICE Recommends BeiGene's BRUKINSA® (zanubrutinib) for Patients with Waldenström's Macr..
BU
09/19NICE Recommends Beigene’s BRUKINSA® (Zanubrutinib) for Patients with Waldenström&#..
CI
09/19BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment o..
BU
09/19BeiGene, Ltd.Receives Positive Committee for Medicinal Products for Human Use Opinion f..
CI
09/19BeiGene's Brukinsa Drug Recommended for EU Authorization
DJ
09/15Beigene, Ltd. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/14Transcript : BeiGene, Ltd. Presents at Morgan Stanley 20th Annual Global Heal..
CI
09/14Beigene, Ltd. Announces Appointment of Member of Compensation Committee
CI
09/13BeiGene's Hepatocellular Carcinoma Study Reaches Primary Endpoint
MT
09/10BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presenta..
BU
09/10BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presenta..
CI
09/07BeiGene to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
BU
09/06China-focused hedge funds lower exposure as risks mount
RE
09/05China-focused hedge funds lower exposure as risks mount
RE
08/31BeiGene Books Wider Loss in H1 as Revenue Plunges 14%
MT
08/29Asian ADRs Move Slightly Higher in Monday Trading
MT
08/29US, China Reach Audit Deal to Prevent Delistings
MT
08/25Beigene, Ltd. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/23BeiGene Says China Regulators Accept sBLA for Tislelizumab Combined With Chemotherapy i..
MT
08/23BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizu..
BU
08/23BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizu..
CI
08/18Asian ADRs Move Lower in Thursday Trading
MT
08/15BeiGene, McKesson Unit to Collaborate to Improve Patient Access to Cancer Drugs
MT
08/15BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Car..
BU
08/15BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Car..
CI
08/10Beigene : Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab ..
PU
08/10Beigene, Ltd. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/10Asian ADRs Move Sharply Higher in Wednesday Trading
MT
08/09JPMorgan Assumes BeiGene at Overweight with $296 Price Target
MT
08/09Novartis-BeiGene Liver Cancer Drug Works As Well As Bayer's Nexavar in Phase 3 Study
MT
08/09BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab..
BU
08/09BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab..
CI
08/08BEIGENE, LTD. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
08/08Nomura Adjusts BeiGene's Price Target to $286.31 From $277.35, Maintains Buy Rating
MT
08/08Nomura Adjusts Beigene's Price Target to HK$172.89 From HK$167.48, Keeps at Buy
MT
08/05Another case of good news is bad news
MS
08/05Analyst recommendations: Eli Lilly, KLA, Kellogg, Epam Systems, ..
MS
08/05BeiGene Shares Gain After Doubling of Second-Quarter Revenue
DJ
08/04BeiGene Q2 Net Loss per ADS Widens as Revenue Rises; Shares Surge
MT
08/04Beigene : Reports Second Quarter 2022 Financial Results - Form 8-K
PU
08/04Earnings Flash (BGNE) BEIGENE Posts Q2 Revenue $341.6M
MT
08/04Beigene, Ltd. : Results of Operations and Financial Condition, Other Events, Financial Sta..
AQ
08/04BeiGene Reports Second Quarter 2022 Financial Results
BU
08/04BeiGene, Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June..
CI
08/01Nomura Adjusts BeiGene's Price Target to $277.35 From $310.62, Maintains Buy Rating
MT
08/01Nomura Adjusts Beigene's Price Target to HK$167.48 From HK$186.85, Keeps at Buy
MT
07/27SEC Chair Stresses Need to Reach Audit Deal With Chinese Regulators
MT
07/26China’s Securities Watchdog Denies Plan to Help Firms Avoid US Delisting
MT
07/20Beigene, Ltd. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
07/20Deal to Avoid Delisting of 200 Firms in US Bourses Remains Unclear
MT
07/15Beigene, Ltd. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
07/15Beigene : Provides Regulatory Update on the U.S. Biologics License Application (BLA) for P..
PU
07/15Morgan Stanley Adjusts BeiGene's Price Target to $293 from $300, Keeps Overweight Ratin..
MT
07/14US FDA Delays Action On Novartis Partner's Biologics License Application For Tislelizum..
MT
07/14Morgan Stanley Adjusts Price Target for BeiGene to $293 From $300, Maintains Overweight..
MT
07/14Sector Update: Health Care Stocks Unable to Climb Back to Positive Ground
MT
07/14Sector Update: Health Care Stocks Declining Thursday with Broader Markets
MT
07/14BeiGene Says US FDA Defers Action on Biologics License Application for Tislelizumab
MT
07/14BeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for ..
BU
07/14Beigene Provides Regulatory Update on the U.S. Biologics License Application for Pd 1 I..
CI
07/14Beigene Says FDA Defers Action on BLA Due to Covid Travel Restrictions
DJ
07/13Asian ADRs Move Lower in Wednesday Trading
MT
07/13BeiGene Appoints Chan Lee as General Counsel
BU
07/13BeiGene, Ltd. Appoints Chan Lee as General Counsel, July 18 2022
CI
07/12Leap Therapeutics, BeiGene Initiate New DKN-01 Trials for Cancers
MT
07/12Leap Therapeutics and BeiGene, Ltd. Announces Initiation of New DKN-01 Clinical Trials ..
CI
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on BEIGENE, LTD.